News | August 09, 2022
Briefs: Zydus Lifesciences and Kimia Biosciences
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Advancing to IND-enabling studies with multiple drug candidates
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Subscribe To Our Newsletter & Stay Updated
